Company / Revenue
LIGAND PHARMACEUTICALS INC Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$268.1M
FY2025
5-year range
$131.3M / $268.1M
FY2021-FY2025
Trend
+60.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 10 years, ranging from $29M in FY2017 to $268M in FY2025.
Based on SEC 10-K filings.
$268M in FY2025 with a 5-year CAGR of +10.4%.
Improved from $131M to $268M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +11.0%
- 5-Year CAGR
- +10.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +10.4%, indicating consistent growth.
- In FY2025, revenue increased 60.4% year-over-year.
- Lowest revenue in the period was in FY2017.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $268.1M | +60.4% |
| FY2024 | $167.1M | +27.3% |
| FY2023 | $131.3M | -33.1% |
| FY2022 | $196.2M | -18.8% |
| FY2021 | $241.5M | +47.7% |
| FY2020 | $163.6M | +36.0% |
| FY2019 | $120.3M | -52.2% |
| FY2018 | $251.5M | +759.2% |
| FY2017 | $29.3M | -73.1% |
| FY2016 | $109.0M | +51.5% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026